A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

This study has been terminated.
Sponsor:
Information provided by:
Exelixis
ClinicalTrials.gov Identifier:
NCT00475917
First received: May 17, 2007
Last updated: October 1, 2010
Last verified: October 2010

May 17, 2007
October 1, 2010
May 2007
May 2009   (final data collection date for primary outcome measure)
  • Safety and tolerability of XL844 as a single agent and in combination with gemcitabine when administered orally to subjects with advanced malignancies [ Time Frame: Assessed at each visit/periodic visits ] [ Designated as safety issue: Yes ]
  • Determine the Combination maximum tolerated dose and dose-limiting toxicities for XL844 alone and in combination with gemcitabine [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: Yes ]
  • Evaluate plasma pharmacokinetics and estimate renal elimination of XL844 as a single agent and in combination with gemcitabine [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: No ]
  • Safety and tolerability of XL844 as a single agent and in combination with gemcitabine when administered orally to subjects with advanced malignancies
  • Determine the Combination maximum tolerated dose and dose-limiting toxicities for XL844 alone and in combination with gemcitabine
  • Evaluate plasma pharmacokinetics and estimate renal elimination of XL844 as a single agent and in combination with gemcitabine
Complete list of historical versions of study NCT00475917 on ClinicalTrials.gov Archive Site
  • (Exploratory:) Assess tumor response after repeated administration of XL844 in combination with gemcitabine in subjects with advanced malignancies [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: No ]
  • Pharmacodynamic correlates of XL844 activity in tumor tissue [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: No ]
  • (Exploratory:) Assess tumor response after repeated administration of XL844 in combination with gemcitabine in subjects with advanced malignancies
  • Pharmacodynamic correlates of XL844 activity in tumor tissue
Not Provided
Not Provided
 
A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Subjects With Advanced Malignancies

The purpose of this study is to determine a safe dose of XL844 in combination with gemcitabine, how often it should be taken, and how well people with cancer tolerate the combination of gemcitabine and XL844.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Cancer
  • Lymphoma
  • Drug: XL844
    Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
  • Drug: Gemcitabine
    once-weekly 30-minute IV infusion
Experimental: 1
Interventions:
  • Drug: XL844
  • Drug: Gemcitabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
63
May 2009
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The subject has a histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no therapies known to prolong survival.
  2. The subject has disease that is assessable by tumor marker, physical, or radiologic means.
  3. The subject is ≥18 years old.
  4. The subject has an ECOG (Eastern Cooperative Oncology Group) performance status of ≤2.
  5. The subject has adequate organ and marrow function.
  6. The subject has the capability of understanding the informed consent document and has signed the informed consent document.
  7. Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study.
  8. Female subjects of childbearing potential must have a negative pregnancy test at screening.
  9. If a subject has received more than three prior regimens of cytotoxic chemotherapy, more than two biologic regimens, or more than 3000 cGy to >25% of his or her bone marrow, the investigator must discuss with the sponsor regarding subject suitability before enrollment.
  10. The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer, in situ carcinoma of the cervix, or a malignancy diagnosed ≥5 years ago, and has had no evidence of disease for 5 years prior to screening for this study).

Exclusion Criteria:

  1. The subject has received anticancer treatment (eg, chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agent, or hormones) within 14 days prior to the first dose of study drug.
  2. The subject has not recovered to Grade ≤1 from adverse events (AEs) due to investigational agents or other medications administered more than 30 days prior to the first dose of study drug.
  3. The subject has received radiation to >25% of his or her bone marrow within 30 days of XL844 treatment.
  4. The subject has a primary brain tumor or known brain metastases.
  5. The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  6. The subject is pregnant or breastfeeding.
  7. The subject is known to be positive for the human immunodeficiency virus (HIV).
  8. The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
  9. The subject has a known allergy or hypersensitivity to any of the components of the XL844 formulation or gemcitabine.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00475917
XL844-002
Not Provided
Salim Yazji, MD/Senior Director, Clinical Research, Exelixis, Inc.
Exelixis
Not Provided
Not Provided
Exelixis
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP